Concomitant inactivation of the epidermal growth factor receptor, phosphatidylinositol 3-kinase/Akt and Janus tyrosine kinase 2/signal transducer and activator of transcription 3 signalling pathways in cardiotoxin III-treated A549 cells

Clinical and Experimental Pharmacology and Physiology

Volumn 37, Issue 8, 2010, Pages 833-840

  Su, Jung Chen ^a   Lin, Kuei Li ^a   Chien, Ching Ming ^a   Chuang, Pei Wen ^b   Chang, Long Sen ^b   Lin, Shinne Ren ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

A549 cells; cardiotoxin III; epidermal growth factor receptor; Janus tyrosine kinase 2 signal transducer and activator of transcription 3; phosphatidylinositol 3 kinase Akt

Indexed keywords

CARDIOTOXIN; CASPASE 3; CASPASE 9; CYTOCHROME C; EPIDERMAL GROWTH FACTOR RECEPTOR; JANUS KINASE 2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLSERINE; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN MCL 1; STAT3 PROTEIN; WORTMANNIN; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL CYCLE G1 PHASE; CELL LINE; CELL POPULATION; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 77955120989     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J. Clin. 2007 57:43 66.
2. Raez LE, Lilenbaum R. Chemotherapy for advanced non-small-cell lung cancer. Clin. Adv. Hematol. Oncol. 2004 2:173 178.
3. Kelly K. The role of targeted agents in adjuvant therapy for non-small cell lung cancer. Clin. Cancer Res. 2005 11 (Suppl. S5027 9.
4. Steinke K. Lung tumors. Recent Results Cancer Res. 2006 167:107 122.
5. Bogdan S, Klambt C. Epidermal growth factor receptor signaling. Curr. Biol. 2001 11 (Suppl. R292 5.
6. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J. Clin. Oncol. 2002 20 (Suppl. S1 13.
7. Arteaga CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin. Oncol. 2002 29 (Suppl. S3 9.
8. Shin DM, Ro JY, Hong WK, Hittelman WN. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res. 1994 54:3153 3159.
9. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000 19:2474 2488.
10. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat. Rev. Mol. Cell Biol. 2001 2:127 137.
11. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002 296:1655 1657.
12. Battle TE, Frank DA. The role of STATs in apoptosis. Curr. Mol. Med. 2002 2:381 392.
13. Yu H, Jove R. The STATs of cancer: New molecular targets come of age. Nat. Rev. Cancer 2004 4:97 105.
14. Salvesen GS, Dixit VM. Caspases: Intracellular signaling by proteolysis. Cell 1997 91:443 446.
15. Adams JM, Cory S. The Bcl-2 protein family: Arbiters of cell survival. Science 1998 281:1322 1326.
16. Antonsson B, Martinou JC. The Bcl-2 protein family. Exp. Cell Res. 2000 256:50 7.
17. Dufton MJ, Hider RC. The structure and pharmacology of Elapid cytotoxins. In:Harvey AL (ed). Snake Toxins. Pergamon Press
18. Chien KY, Huang WN, Jean JH, Wu WG. Fusion of sphingomyelin vesicles induced by proteins from Taiwan cobra (Naja naja atra) venom Interaction of zwitterionic phospholipids with cardiotoxin analogues. J. Biol. Chem. 1991 266:3235 3259.
19. Guo MP, Wang QC, Liu GF. Pharmacokinetics of cytotoxin from Chinese cobra (Naja naja atra) venom. Toxicon 1993 31:339 343.
20. Chiou SH, Raynor RL, Zheng B, Chambars TC, Kuo JF. Cobra venom cardiotoxin (cytotoxin) isoforms and neurotoxin: Comparative potency of protein kinase C inhibition and cancer cell cytotoxicity and model of enzyme inhibition. Biochemistry 1993 32:2062 2067.
21. Yang SH, Chien CM, Lu MC, Lu YL, Wu ZZ, Lin SR. Cardiotoxin III induces apoptosis in K562 cells through a mitochondrial-mediated pathway. Clin. Exp. Pharmacol. Physiol. 2005 32:515 520.
22. Yang SH, Lu MC, Chien CM et al. Induction of apoptosis in human leukemia K562 cells by cardiotoxin III. Life Sci. 2005 76:2513 2522.
23. Chien CM, Yang SH, Lu MC, Chang LS, Lin SR. Cardiotoxin III induces apoptosis in T24 cells via reactive oxygen species-independent mitochondrial death pathway. Drug Dev. Res. 2004 63:219 224.
24. Tsai CH, Yang SH, Chien CM et al. Mechanism of cardiotoxin III-induced apoptosis in human colorectal cancer Colo 205 cells. Clin. Exp. Pharmacol. Physiol. 2006 33:177 182.
25. Chien CM, Yang SH, Yang CC, Chang LS, Lin SR. Cardiotoxin III induces c-Jun N-terminal kinase-dependent apoptosis in HL-60 human leukemia cells. Cell Biochem. Funct. 2008 26:111 118.
26. Chiu CC, Lin KL, Chien CM, Chang LS, Lin SR. Effects of cardiotoxin III on NFκB function, proliferation and apoptosis in human breast MCF-7 cancer cells. Oncol. Res. 2009 17:311 321.
27. Chien CM, Lin KL, Su JC, Chang LS, Lin SR. Inactivation of epidermal growth factor receptor and downstream pathways in oral squamous cell carcinoma Ca9-22 cells by cardiotoxin III from Naja naja atra. J. Nat. Prod. 2009 72:1735 1740.
28. Lin SR, Chang LS, Chang KL. Separation and structure-function studies of Taiwan cobra cardiotoxins. J. Protein Chem. 2005 21:81 6.
29. Henry-Mowatt J, Dive C, Martinou JC, James D. Role of mitochondrial membrane permeabilization in apoptosis and cancer. Oncogene 2004 23:2850 2860.
30. Levitzki A, Gazit A. Tyrosine kinase inhibition: An approach to drug development. Science 1995 267:1782 1788.
31. Liu W, Akhand AA, Kato M et al. 4-Hydroxynonenal triggers an epidermal growth factor receptor-linked signal pathway for growth inhibition. J. Cell Sci. 1999 112:2409 2417.
32. Jiang X, Wang X. Cytochrome c promotes caspase-9 activation by inducing nucleotide binding to Apaf-1. J. Biol. Chem. 2000 275:31.
33. Datta SR, Brunet A, Greenberg ME. Cellular survival: A play in three Akts. Genes Dev. 1999 13:2905 2927.
34. Huang SH, Chen Y, Tung PY et al. Mechanisms for the magnolol-induced cell death of CGTH W-2 thyroid carcinoma cells. J. Cell. Biochem. 2007 101:1011 1022.
35. Kuo PL, Ni WC, Tsai EM, Hsu YL. Dehydrocostuslactone disrupts signal transducers and activators of transcription 3 through up-regulation of suppressor of cytokine signaling in breast cancer cells. Mol. Cancer Ther. 2009 8:1328 1339.
36. Kurebayashi J, Okubo S, Yamamoto Y et al. Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells. Cancer Chemother. Pharmacol. 2006 58:460 470.
37. Willis SN, Chen L, Dewson G et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005 19:1294 1305.
38. Ou YC, Yang CR, Cheng CL et al. Indomethacin causes renal epithelial cell injury involving Mcl-1 down-regulation. Biochem. Biophys. Res. Commun. 2009 380:531 536.
39. Pugazhenthi S, Nesterova A, Sable C et al. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-responsive element-binding protein. J. Biol. Chem. 2000 275:10.
40. She QB, Solit DB, Ye Q, O'Reilly KE, Lobo J, Rosen N. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt knase pathwaysin PTEN-deficient tumor cells. Cancer Cell 2005 8:287 297.